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ABSTRACT 
Background: Unlike heart failure with reduced ejection fraction, there is no approved 
treatment for heart failure with preserved ejection fraction (HFpEF), the predominant 
phenotype in women. Therefore, there is a greater heart failure therapeutic deficit in women, 
compared with men. 
Methods:  In a pre-specified subgroup analysis, we examined outcomes according to sex in 
the PARAGON-HF trial which compared sacubitril-valsartan and valsartan in patients with 
HFpEF. The primary outcome was a composite of first and recurrent hospitalizations for 
heart failure and death from cardiovascular causes. We also report secondary efficacy and 
safety outcomes. 
Results: Overall, 2479 women (51.7%) and 2317 men (48.3%) were randomized. Women 
were older, had more obesity, less coronary disease, and lower estimated glomerular filtration 
rate and NT-proBNP levels than men. For the primary outcome, the rate ratio for sacubitril-
valsartan versus valsartan was 0.73 (95% CI 0.59-0.90) in women and 1.03 (0.84-1.25) in 
men; P interaction=0.017. The benefit from sacubitril-valsartan was due to reduction in heart 
failure hospitalization. The improvement in NYHA class and renal function with sacubitril-
valsartan was similar in women and men, whereas the improvement in KCCQ-CSS was less 
in women than in men. The difference in adverse events, between sacubitril-valsartan and 
valsartan, was similar in women and men. 
Conclusion: As compared with valsartan, sacubitril-valsartan seemed to reduce the risk of 
heart failure hospitalization more in women than in men. While the possible sex-related 
modification of the effect of treatment has several potential explanations, the present study 
does not provide a definite mechanistic basis for this finding. 
Clinical Trial Registration: PARAGON-HF: ClinicalTrials.gov Identifier NCT01920711 
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CLINICAL PERSPECTIVE 
What is new? 
• Women represent approximately a quarter of people with HF and reduced EF 
(HFrEF) and over half of those with HF and preserved EF (HFpEF). 
• There are multiple effective drug and device therapies for HFrEF, but none approved 
for HFpEF; thus, there is a greater heart failure “therapeutic deficit” in women, 
compared with men.  
• In PARAGON-HF, sex and LVEF appeared to modify the effect of sacubitril-
valsartan, versus valsartan, on the primary outcome (total heart failure 
hospitalizations and cardiovascular death), with a more favorable treatment effect in 
women than in men (rate ratio 0.73 (0.59-0.90) in women, 1.03 (0.84-1.25) in men; P 
interaction=0.017). 
What are the clinical implications? 
• While the apparent sex-related modification of the effect of sacubitril-valsartan has 
several potential explanations, the present study does not provide a definite 
mechanistic basis for this finding.  
• Our findings raise the possibility that the effects of pharmacological treatments for 
HFpEF may differ between men and women.  
• This hypothesis should be investigated further, given the therapeutic deficit in this 
heart failure phenotype in general and, particularly, in women. 
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INTRODUCTION 
Healthy women, on average, have higher a left ventricular ejection fraction (LVEF) than men 
and the pattern of left ventricular remodeling seen in response to increased afterload and with 
aging differs between women and men. 1-6 Among patients with heart failure (HF), women 
are less likely than men to have a markedly reduced LVEF (i.e. ≤40%).1-6 While women 
represent approximately a quarter of people with HF and reduced EF (HFrEF), they account 
for over half of those with HF and preserved EF (HFpEF). 1-6 Although there are multiple 
effective drug and device therapies for HFrEF, there are none with regulatory approval for 
the treatment of HFpEF and guidelines largely focus on management of hypertension and 
volume overload and treatment of concomitant comorbidities such as atrial fibrillation .7,8 In 
addition, the 2017 update of the American College of Cardiology/American Heart 
Association/Heart Failure Society of America guidelines gave a Class IIb Level B-R 
recommendation for an aldosterone receptor antagonist in selected patients with HFpEF.8 For 
this and other reasons, there is a greater heart failure “therapeutic deficit” in women, 
compared with men.1,5,6   
In PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in Heart 
Failure with Preserved Ejection Fraction trial), the effects of sacubitril-valsartan were 
compared with those of valsartan, and the primary outcome was a composite of heart failure 
hospitalization (first and repeat) and cardiovascular death.9-11  Among the 4796 participants 
analyzed (52% women), there were fewer primary endpoints in the sacubitril-valsartan group, 
compared with the valsartan group, although the difference was of borderline statistical 
significance (894 versus 1009 primary events; rate ratio, 0.87; 95% confidence interval [CI], 
0.75 to 1.01; P = 0.059).  In PARAGON-HF, there were 12 pre-specified subgroup 
analyses.11 Of these, only sex and LVEF appeared to modify the effect of sacubitril-valsartan 
versus valsartan on the primary composite outcome, with a more favorable treatment effect in 
women than in men. In view of the potential importance of this finding, we defined, in detail, 
6 
 
the differences between women and men in PARAGON-HF and further investigated the 
interaction between sex and the effect of treatment. 
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METHODS 
The design and primary results of the PARAGON-HF trial are published.9-11 The Ethics 
Committee of each of the participating institutions approved the protocol, and all patients 
gave written, informed consent. Novartis is committed to sharing, with qualified external 
researchers, access to patient-level data and supporting clinical documents from eligible 
studies. These requests are reviewed and approved by an independent review panel on the 
basis of scientific merit. All data provided are anonymized to respect the privacy of patients 
who have participated in the trial in line with applicable laws and regulations. The trial data 
availability is according to the criteria and process described 
on www.clinicalstudydatarequest.com. 
 
Study patients 
Eligibility for the study included New York Heart Association (NYHA) class II-IV 
symptoms, an ejection fraction of 45% or higher at, or within 6 months of, screening, an 
elevated natriuretic peptide level, evidence of structural heart disease and diuretic therapy. 
The natriuretic peptide level threshold for inclusion varied according to whether there had 
been a recent hospitalization for heart failure and the presence of atrial fibrillation or flutter. 
The main exclusion criteria included any prior echocardiographic measurement of  LVEF 
<40%, recent acute coronary syndrome, cardiac surgery or percutaneous coronary 
intervention, acute decompensated heart failure at the time of screening, intolerance to either 
study drug (or similar classes) or a history of angioedema, systolic blood pressure >180 
mmHg  or <110mmHg, estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m2 and 
serum potassium >5.2 mmol/l. 
 
Trial procedures 
All patients initially received valsartan at half the target dose (single-blind run-in period) and 
then sacubitril-valsartan at half the target dose (single-blind run-in period). If tolerated, 
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patients were then randomized to treatment with either sacubitril-valsartan or valsartan in a 
1:1 fashion. The target doses were sacubitril-valsartan 97mg/103mg twice daily or 160mg of 
valsartan twice daily. The 103 mg of valsartan in sacubitril-valsartan is equivalent to 160 mg 
of the standard valsartan formulation. 
Trial outcomes 
The primary outcome was a composite of first and recurrent hospitalizations for heart failure 
and death from cardiovascular causes. Secondary outcomes were the change in the Kansas 
City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS12)  from baseline to 
8 months (with a score from 0-100 and higher scores corresponding to fewer symptoms and 
limitations), change in NYHA class from baseline to 8 months, the time to the first 
occurrence of a decline in renal function (defined as a reduction of 50% of more in estimated 
glomerular filtration rate, development of end-stage renal disease or death due to renal 
failure) and time to death from any cause. Safety outcomes included hypotension (defined as 
a systolic blood pressure <100mmHg), elevation of serum creatinine, elevation of serum 
potassium, and angioedema  
 
Statistical analysis 
The trial was designed to recruit 4600 patients and continue until 1847 primary events 
occurred. Between 2014 and 2016, 10, 359 patients in 43 countries were screened and a total 
of 4796 patients were finally included.  In the present study, patients were analyzed 
according to sex (baseline characteristics were compared using t-tests, Wilcoxon rank-sum 
test, and chi-squared tests where appropriate). The primary composite outcome, its 
components, change in KCCQ-CSS from baseline to 8 months, change in NYHA class from 
baseline to 8 months and death from any cause were analyzed, as was safety. An additional 
expanded primary composite outcome, which included urgent heart failure visits, was also 
analyzed. For each sex, the effect of sacubitril-valsartan compared with valsartan on the 
primary composite outcome, its components, and the expanded primary composite outcome 
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was examined using the semiparametric proportional rates method of Lin et al stratified 
according to region.13 The cumulative recurrent events were displayed using Nelson-Aalen 
cumulative hazard curves and cumulative first events were displayed using Kaplan-Meier 
curves. The primary composite outcome and its components were also analyzed using Cox 
regression for time-to-first event, as were the renal composite outcome and death from any 
cause.  Changes from baseline to 8 months in KCCQ-CSS, systolic blood pressure and pulse 
pressure, and from baseline to 1 year in N-terminal pro-B-type natriuretic peptide (NT-
proBNP) and urinary cyclic guanosine monophosphate (cGMP)/creatinine, were analyzed 
using a repeated measures analysis of covariance model, together with the mixed-effect 
logistic responder analyses for a 5-point or greater change in KCCQ-CSS. Change from 
baseline to 8 months in NYHA class was analyzed using a repeated measures proportional 
cumulative odds model. The interaction between sex and treatment on each outcome was 
assessed in each respective statistical test and in a logistic regression model for the safety 
outcomes.  Models were adjusted for differences in baseline characteristics between women 
and men (specifically, age, heart rate, systolic blood pressure, body mass index, smoking 
status, NT-proBNP (log), eGFR, NYHA class, LVEF, prior HF hospitalization, myocardial 
infarction, diabetes and atrial fibrillation); analyses were either stratified (prespecified 
primary and secondary outcomes) or adjusted for geographical region. A fractional 
polynomial was constructed using left ventricular ejection fraction and entered into the model 
as an interaction term with treatment. The results of the interaction were displayed 
graphically using the mfpi command in STATA. The effect of sacubitril-valsartan compared 
with valsartan was modelled over the spectrum of left ventricular ejection fraction in women 
and men separately. All analyses were conducted using STATA version 16 (College Station, 
TX: StataCorp LLC). A P value of <0.05 was considered statistically significant. 
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RESULTS 
Patient characteristics 
Overall, 2479 women (51.7%) and 2317 men (48.3%) were randomized. Women were older 
than men and had more obesity and a lower median NT-proBNP level and a lower mean 
eGFR than men (Table 1).  The distribution of LVEF in women and men is shown in 
Supplemental Figure 1.  The median LVEF in women was 60% and in men it was 55%. 
Women had a worse NYHA class distribution, worse KCCQ-CSS (and overall summary 
score), and more symptoms of heart failure.  Women were much less likely than men to be a 
current or past smoker and had a lower prevalence of coronary heart disease, diabetes and 
chronic obstructive pulmonary disease.  Women were significantly less likely than men to be 
treated with each of a nitrate, statin, antiplatelet therapy, an anticoagulant and a 
mineralocorticoid receptor antagonist. Baseline characteristics were balanced between 
treatment groups, in both women and men (Supplemental Tables 1 and 2). 
 
Clinical outcomes: women versus men (control group) 
Comparison of event rates in the control (valsartan) group showed that women and men had 
similar rates of the composite of heart failure hospitalization or death from cardiovascular 
causes, whether analyzed as total events, including first and recurrent hospitalizations (Figure 
1) or as time-to-first event (Figure S2).  When the components of this composite were 
analyzed individually, women were observed to have higher rates of heart failure 
hospitalization and lower rates of cardiovascular death (and death from any cause), as 
compared with men (Table 2, Figure 1 and S2).  The proportions of women and men reported 
to have an improvement in NYHA Class between baseline and 8 months was similar, but the 
proportion of women describing a clinically important increase in KCCQ-CSS over this 
period was greater than the corresponding proportion in men (Table 2). 
 
Effect of sacubitril-valsartan: women versus men 
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The rate ratio for the primary outcome with sacubitril-valsartan, compared to valsartan, in 
women was 0.73 (95% CI 0.59-0.90) and in men it was 1.03 (0.84-1.25); P interaction=0.017 
(Table 2 and Figure 1).  Adjustment for the baseline differences between women and men did 
not change this result (Table 2).  An alternative approach to analysis of recurrent events 
(negative binomial method) gave qualitatively similar findings to the LWYY method (Figure 
S3). The composite of heart failure hospitalization or cardiovascular death, analyzed as time 
to first event, gave similar findings to the analysis of total events (Table 2 and Figure S2). 
 
Further examination of the apparent benefit of sacubitril-valsartan over valsartan, in women, 
showed that the effect was predominantly related to heart failure hospitalization, with no 
discernible reduction in death from cardiovascular causes (or from any cause) (Table 2, 
Figures 1 and S2).  The magnitude of the effect on first and recurrent hospitalizations for 
heart failure was substantial, with a 33 (95% CI 15-47)% relative risk reduction in women; P 
interaction=0.005 for effect in women versus men. Analysis of first hospitalizations for heart 
failure gave similar findings to total (first and recurrent) admissions (Figure S2).  
 
Examination of the effect of treatment across the range of LVEF studied suggested more 
benefit from sacubitril-valsartan at a lower LVEF, whether using analysis of total events 
(Figure 2) or analyzing first events only (Figure S4).  These fractional polynomial analyses 
also suggested that the upper threshold at which benefit diminished was higher in women 
than in men (Figures 2 and S4). 
 
The proportional improvement in NYHA class with sacubitril-valsartan was similar in 
women and men, whereas the relative improvement in KCCQ-CSS seemed to be less in 
women than in men (although in this “responder analysis”, examining patients with a ≥5-
point improvement, there was no statistically significant interaction between sex and 
response to sacubitril-valsartan). When examined as a continuous variable, the sacubitril-
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valsartan versus valsartan difference in KCCQ-CSS change was also more favorable in men, 
compared with women (P interaction=0.038, adjusted P interaction=0.067). 
 
The improvement in renal function with sacubitril-valsartan, compared with valsartan, was 
similar in women and men (Table 2). 
 
New-onset atrial fibrillation 
The risk of new-onset atrial fibrillation was higher in women treated with sacubitril-valsartan, 
compared with valsartan, whereas the opposite was true for men. Although this resulted in a 
significant interaction between sex and the effect of treatment, the numbers of events were 
small. 
 
Other measures: change in NT-proBNP, systolic blood pressure and pulse pressure and 
urinary cGMP/creatinine 
The reductions from baseline to 8 months in systolic blood pressure and pulse pressure, and 
from baseline to 1 year in NT-proBNP, with sacubitril-valsartan, as compared with valsartan, 
were similar in men and women (Table 2). The increase from baseline to 1 year in urinary 
cGMP to creatinine ratio with sacubitril-valsartan treatment was also similar in women and 
men (Table 2). 
 
Effect of sacubitril-valsartan: Safety in women versus men 
Hypotension was more common, and increases in creatinine and potassium less common, 
with sacubitril-valsartan, as compared with valsartan (Table 3).  The difference in these 
adverse events of interest, between sacubitril-valsartan and valsartan, was similar in women 
and men. There were too few cases of angioedema for meaningful analysis by sex.   
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DISCUSSION 
 
Over half the participants in PARAGON-HF were female, representing one of the largest 
populations of women with HFpEF ever studied. We found that women and men with HFpEF 
have distinct clinical profiles and that, compared with valsartan, treatment with sacubitril-
valsartan led to a greater reduction in heart failure hospitalization in women, than in men. 
The difference in the clinical profile between men and women with HFpEF is consistent with 
prior results, particularly in relation to the lower risk of death and greater severity of 
symptoms in women.1-6 That we observed a greater treatment effect on heart failure 
hospitalization in women than men, is more novel, and of some interest, given that HFpEF is 
the predominant phenotype in women.1-6  Indeed, the proportion of HFpEF in the population 
may be even higher than in PARAGON-HF as, in keeping with trials in general, our patients 
were younger and had less comorbidity than reported in epidemiologic studies.3,5,6 
 
The major question arising is whether this subgroup finding was due to the play of chance or 
represents a real difference between women and men in response to therapy?  A framework 
for interpretation of treatment heterogeneity in subgroups has been provided by several 
authors.14-17 Key principles include pre-specification of the subgroup of interest, that the 
subgroup should be of sufficient size and that a statistical test for interaction is carried out.  
Each of these conditions was fulfilled in the present study and in a further step, an interaction 
between sex (along with ejection fraction) and the effect of treatment persisted in a 
multivariable analysis including all pre-specified subgroups.11 
 
Other key considerations are biological plausibility and internal consistency and external 
validation.  In terms of the first of these, there are several reasons why women might have a 
more favorable response to neprilysin inhibition.  The normal LVEF range is higher in 
women than in men, reflecting sex-related differences in cardiac remodeling in response to 
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blood pressure, age etc.3-6,18  Importantly, for a given LVEF, more women than men may 
have other evidence of contractile dysfunction.2-6,19,20 If correct, this would mean that more 
women than men in the present study had mild left ventricular systolic dysfunction. This 
view is consistent with the apparent benefit of sacubitril-valsartan, a drug clearly effective in 
patients with left ventricular systolic dysfunction, to a higher LVEF value in women, 
compared with men, in the fractional polynomial analyses (Figure 2). 
   
Alternatively, age-related arterial stiffening is more pronounced in women than men and has 
been postulated to be a key pathophysiologic factor in HFpEF.21 However, the reduction in 
pulse-pressure (and systolic blood pressure) with sacubitril-valsartan (compared with 
valsartan) was similar in women and men, pulse-pressure is a relatively crude measure of 
arterial stiffness.22   
 
We confirmed that natriuretic peptide levels are lower in women with HFpEF, than in men, 
despite more severe symptoms and known higher left ventricular diastolic and systolic 
stiffness, and filling pressures, in women, compared with men.2-6, 19 However, women have 
much more visceral obesity than men with HFpEF (as evidenced by waist circumference in 
the present study) and obesity is associated with lower natriuretic peptide levels. There are 
also known sex differences in natriuretic peptide biology, with “cross talk” between these 
peptides and sex hormones, possibly leading to a decrease in natriuretic peptide levels after 
the menopause.5,23-28 This potential relative natriuretic peptide deficiency will lead to reduced 
cGMP-protein kinase G (PKG) signaling.24-31 Any reduction in cGMP-PKG signaling due to 
a relative natriuretic peptide deficiency may be exacerbated in postmenopausal women by of 
loss of alternative, estrogen-dependent, stimulation of this pathway through endothelial nitric 
oxide synthase activation and nitric oxide generation.5, 24-31 Consequently, by augmenting 
natriuretic peptides, sacubitril-valsartan may be of greater benefit in women, than in men, if 
women are viewed as having deficient cGMP-PKG signaling. 5, 24-31 Certainly, the increase in 
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urinary cGMP/creatinine with sacubitril-valsartan, was as large in women as in men. The 
present trial, however, does not provide direct mechanistic evidence to support this 
hypothesis. 
 
Neprilysin also degrades other biologically active peptides and it is possible that there could 
be a sex-related difference in these alternative actions of sacubitril-valsartan. Women may 
have a greater increase than men in bradykinin production with neprilysin inhibition as they 
are more likely to develop angioedema than men with both neprilysin and angiotensin-
converting enzyme (ACE) inihibition.32 
 
A much smaller proportion of women, compared with men, were current or former smokers 
which may be relevant because in a population study, smoking was the variable most strongly 
associated with plasma neprilysin level.33 However, adjustment for smoking status did not 
change the apparently greater effect of sacubitril-valsartan in women, compared with men.  
 
We also considered whether the precipitants of heart failure hospitalization might differ 
between women and men, one of which is new-onset atrial fibrillation.34 Confirmed new-
onset atrial fibrillation was relatively infrequent in the trial and the effect of sacubitril-
valsartan on this outcome was less favorable in women than men. This means that incident 
atrial fibrillation cannot account for the sex-related difference in the effect of sacubitril-
valsartan on heart failure hospitalization. 
 
Finally, there may have been a larger subgroup of patients not responsive to treatment with 
sacubitril-valsartan among men, compared with women, in PARAGON-HF e.g. patients with 
undiagnosed cardiac amyloidosis or genetic hypertrophic cardiomyopathy, although it is 
uncertain whether these conditions are more prevalent in males than females with HFpEF.35  
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From the point of view of internal consistency, we found that improvements in patient-
reported and physician-reported outcomes did not show greater improvements with 
sacubitril-valsartan in women, compared with men. Indeed, change in KCCQ-CSS showed a 
more favorable response to sacubitril-valsartan in men, than in women. This may reflect the 
much worse KCCQ scores at baseline in women (with less possibility of improvement) or 
may reflect the play of chance. NYHA class improved to a similar extent in women and men. 
While there is a relatively weak correlation between functional class and health-related 
quality of life and risk of hospital admission, it is still somewhat surprising that the sex-
related responses to sacubitril-valsartan were directionally different for these outcomes. The 
improvement in renal function with sacubitril-valsartan over valsartan, was similar in women 
and men. Overall, therefore, sacubitril-valsartan had similar (or greater, in the case of KCCQ-
CSS) benefits in men as women, with the exception of reduction in heart failure 
hospitalization, which was greater in women. 
 
In terms of external validation, sex does seem to modify response to some treatments in 
patients with heart failure.  In HFrEF, women appear to obtain more benefit from cardiac 
resynchronization therapy but less from digoxin.36,37 In HFpEF, sex-specific spline analysis 
examining the effect of spironolactone across the range of LVEF studied in TOPCAT 
(Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist), 
showed that women appeared to benefit across the whole LVEF spectrum, whereas in men 
there was only benefit at a lower ejection fraction.38 Unpublished data from the CHARM-
Preserved  (Candesartan in Heart Failure Assessment of Reduction in Mortality and 
morbidity) trial report the same pattern (Supplemental Figure 5).39 While these examples 
support the possibility of sex as a modifier of treatment effect, no such interaction was found 
for sacubitril-valsartan (compared with enalapril) in patients with HFrEF in PARADIGM-
HF, suggesting that any modification of the effect of this treatment by sex is only apparent at 
higher ejection fractions.40 However, direct comparison of PARADIGM-HF and PARAGON-
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HF is not straightforward as the comparator therapy in the former trial was enalapril and there 
is less evidence for benefit of ACE inhibitors, compared with angiotensin receptor blockers 
(ARBs), in women, and the comparator therapy in PARAGON-HF was an ARB.39,41 The 
possible discrepancy in sex differences in treatment response by type of HF (HFpEF versus. 
HFrEF) also seems to be the case for mineralocorticoid receptor antagonists (MRAs) when 
the findings of TOPCAT (see above) are compared with the HFrEF trials using MRAs and 
for candesartan (CHARM reduced LVEF trials compared with CHARM-Preserved).39, 42 
 
It is also important to note that PARAGON-HF was an active-controlled trial and, therefore, 
the possible benefit of sacubitril-valsartan over valsartan in women could reflect lower 
efficacy of valsartan in women (compared with men), though this is not supported by 
published analyses of trials using ARBs in HFrEF. 39,41  
 
We also believe that it is unlikely that a greater degree of neprilysin inhibition or angiotensin 
receptor blockade in women might explain the apparent difference between women and men 
in response to sacubitril-valsartan.43 Women did not achieve a higher target dose of 
sacubitril-valsartan than men and did not have a lower treatment discontinuation-rate.  
Moreover, the pharmacokinetics of sacubitril-valsartan and its metabolites do not differ in 
women and in men.44 As mentioned above, the reduction in blood pressure and NT-proBNP, 
and rise in urinary cGMP, was similar in women and men. Collectively, this information 
makes it unlikely that a greater effective dose leading to a greater neprilysin inhibition or 
angiotensin receptor blockade could account for the difference between women and men with 
respect to heart failure hospitalization.   
 
As with any study of this type there are some limitations.  We do not have information on 
more sensitive measures of left ventricular systolic function than ejection fraction. We do not 
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have information on cardiac and other biomarkers, including neprilysin levels or sex 
hormones, except for NT-proBNP and cGMP. 
 
In summary, as compared with valsartan, sacubitril-valsartan seemed to reduce the risk of 
heart failure hospitalization more in women than in men. While the possible sex-related 
modification of the effect of treatment has several potential explanations, the present study 
does not provide a definite mechanistic basis for this finding. 
 
Funding Sources 
JJVM is supported by a British Heart Foundation Centre of Research Excellence Grant 
(RE/18/6/34217) and AMJ is supported by a British Heart Foundation Clinical Research 
Training Fellowship (FS/18/14/33330). 
 
Authors and Affiliations 
John JV McMurray* MD1, Alice M Jackson* MBChB1, Carolyn SP Lam MB BS PhD2,3,4, 
Margaret M Redfield MD5,  Inder S Anand MD6, Junbo Ge MD7, Marty P Lefkowitz MD8, 
Aldo P Maggioni MD9, Felipe Martinez MD10, Milton Packer MD11, Marc A Pfeffer MD 
PhD12, Burkert Pieske MD13, Adel R Rizkala Pharm.D8, Shalini V Sabarwal Pharm.D8, Amil 
M Shah MD12, Sanjiv J Shah MD14, Victor C Shi MD8, Dirk J van Veldhuisen MD3, Faiez 
Zannad MD15, Michael R Zile MD16, Maja Cikes MD17, Eva Goncalvesova MD18, Tzvetana 
Katova MD19, Anamaria Kosztin MD, PhD20, Malgorzata Lelonek MD21, Nancy Sweitzer 
MD22, Orly Vardeny PharmD MS23, Brian Claggett PhD12, Pardeep S Jhund MD1, Scott D 
Solomon MD12 
 
1BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; 2National 
Heart Center Singapore and Duke–National University of Singapore, Singapore; 3Department 
19 
 
of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, 
the Netherlands; 4The George Institute for Global Health, Australia; 5Mayo Clinic, Rochester; 
6University of Minnesota, Minneapolis; 7Shanghai Institute of Cardiovascular Diseases; 
8Novartis Pharmaceuticals, East Hanover, NJ; 9National Association of Hospital 
Cardiologists Research Center, Florence; 10National University of Cordoba, Cordoba, 
Argentina; 11Baylor University Medical Center, Dallas; 12Cardiovascular Division, Brigham 
and Women’s Hospital, Harvard Medical School, Boston; 13Department of Internal Medicine 
and Cardiology, German Center for Cardiovascular Research partner site Berlin; 14Division 
of Cardiology, Department of Medicine, Northwestern University Feinberg School of 
Medicine, Chicago; 15INSERM Centre d’Investigation Clinic 1433 and Universite de 
Lorraine, Centre Hospitalier Regional et Universitaire, Nancy, France; 16Medical University 
of South Carolina and the Ralph H. Johnson Department of Veterans Affairs Medical Center, 
Charleston; 17University Hospital Centre Zagreb, Zagreb, Croatia; 18Department of Heart 
Failure–Transplantation, National Cardiovascular Institute, Bratislava, Slovakia; 19Clinic of 
Cardiology, National Cardiology Hospital, Sofia, Bulgaria; 20Heart and Vascular Center, 
Semmelweis University, Hungary; 21Department of Noninvasive Cardiology, Medical 
University of Lodz, Lodz, Poland; 22University of Arizona Sarver Heart, Tuscon, Arizona, 
USA; 23Minneapolis VA Center for Care Delivery and Outcomes Research, Associate 
Professor of Medicine, University of Minnesota. 
* Both authors contributed equally to this manuscript 
 
Conflict of Interest Disclosures 
AMJ reports no conflicts. JJVM reports that his employer, Glasgow University, has been paid 
by Novartis for serving as an Executive Committee member and co-principal investigator of 
ATMOSPHERE, PARADIGM-HF and PARAGON-HF trials and Executive/Steering 
Committee member of the PARADISE-MI and PERSPECTIVE trials (with sacubitril-
20 
 
valsartan) and for meetings/presentations related to these trials, aliskiren, and sacubitril-
valsartan. Novartis has also paid for his travel and accommodation for some of these 
meetings, Glasgow University has also been paid by Novartis for advisory board, by Bayer 
for serving as a Steering Committee member of the PANACHE trial using neladenoson 
bialanate (BAY 1067197), by Cardiorentis for serving as a Steering Committee member and 
Endpoint committee Chair for the TRUE-AHF trial and attending meetings related to this 
trial, by Cardiorentis for travel and accommodation to attend some of these meetings, by 
Amgen for serving as Steering Committee member for the ATOMIC-HF and COSMIC-HF 
trials and attending meetings related to this trial, by Amgen for travel and accommodation for 
some of these meetings, by Oxford University (who received a grant from Bayer who 
manufacture acarbose) for serving as a Steering Committee member for the ACE trial (using 
acarbose) and attending meetings related to this trial, by Theracos for serving as Principal 
Investigator for the BEST trial and attending meetings related to this trial, by Theracos for 
travel and accommodation to attend some of these meetings, by Abbvie (who manufacture 
atrasentan) for serving as Steering Committee member for the SONAR trial (using 
atrasentan) and to attend meetings related to this trial, by Abbvie has for his travel and 
accommodation to attend some of these meetings, by DalCor Pharmaceuticals for serving as 
Steering Committee member for the Dal-GenE trial and to attend meetings related to this 
trial; by Pfizer for serving on the Data Safety Monitoring Committee for the SPIRE trial and 
to attend meetings related to this trial, by Merck for serving on the Data Safety Monitoring 
Committee for the MK-3102 program, for the VICTORIA trial, and to attend meetings 
related to these trials, by AstraZeneca (who market dapagliflozin) for serving as Principal 
Investigator of DAPA-HF and Co-principal Investigator of DELIVER (trials using 
dapagliflozin on heart failure) and to attend meetings related trial, by AstraZeneca for his 
travel and accommodation to attend meetings; by GSK for serving as Co-principal 
Investigator and Steering Committee member, respectively, for the Harmony-Outcomes trial 
(albiglutide) and two trials, ASCEND-D and ASCEND-ND, using daprodustat, and to attend 
21 
 
meetings related to these trials, by GSK for his travel and accommodation to attend some of 
the meetings, by BMS for serving as a Steering Committee member for the STAND-UP 
clinical trial (using a HNO donor) on heart failure and to attend meetings related to this trial, 
by Kings College Hospital (who have received a grant from KRUK and Vifor-Fresenius who 
manufacture intravenous iron) for serving as Steering Committee member for the PIVOTAL 
trial (using intravenous iron) and for running the Endpoint Adjudication Committee for this 
trial, to attend meetings related to PIVOTAL, and for his travel and accommodation for to 
attend some of the meetings. All payments were made through Consultancies with Glasgow 
University and JJVM has not received any personal payments in relation to the trials/or 
drugs. CSPL reports receiving grant support and fees for serving on an advisory board from 
Boston Scientific and Roche Diagnostics, grant support, fees for serving on an advisory 
board, and fees for serving on steering committees from Bayer, grant support from 
Medtronics, grant support and fees for serving on a steering committee from Vifor Pharma, 
fees for serving on an advisory board and fees for serving on steering committees from 
AstraZeneca and Novartis, fees for serving on an advisory board from Amgen, Boehringer 
Ingelheim, and Abbott Diagnostics, consulting fees from Merck and Stealth BioTherapeutics, 
fees for serving on a steering committee from Janssen Research and Development, lecture 
fees and consulting fees from Menarini, and fees for serving on a scientific committee from 
Corvia Medical and holding a pending patent (PCT/SG2016/050217) on a method regarding 
diagnosis and prognosis of chronic heart failure . MMR reports being a non-paid consultant 
or Novartis. ISA reports receiving fees for serving on a steering committee from 
AstraZeneca, ARCA Biopharma, Amgen, and LivaNova, fees for serving as chair of a data 
and safety monitoring board from Boston Scientific, fees for serving on an end-point 
committee from Boehringer Ingelheim, and fees for serving on an advisory board from 
Zensun. JG reports no conflicts. MPL, ARR, SVS, VCS and OV are salaried employees of 
Novartis and ARR owns Novartis stock. APM reports receiving fees for serving on a study 
committee from Bayer and Fresenius. FM reports receiving personal fees from Novartis. MP 
22 
 
reports receiving consulting fees from Abbvie, Akcea, Actavis, Amgen, AstraZeneca, Bayer, 
Boehringer Ingelheim, Cardiorentis, Daiichi Sankyo, Gilead, Johnson & Johson, 
NovoNordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. MAP reports 
grants paid to his institution, for serving on the Steering Committee of PARAGON-HF, and 
for serving as Study Chair of PARADISE-MI from Novartis and personal fees for consulting 
from AstraZeneca, DalCor, GlaxoSmithKline, NovoNordisk, Sanofi, Jazz Pharmaceuticals, 
MyoKardia, Servier, Takeda, Corvidia. MAP also owns Stock Options of DalCor. BP reports 
receiving fees for serving on a steering committee, fees for serving on an advisory board, and 
lecture fees from Bayer HealthCare Pharmaceuticals and MSD, lecture fees from 
AstraZeneca, fees for serving on an advisory board and lecture fees from Bristol-Myers 
Squibb, fees for serving on an advisory board from Daiichi Sankyo, and lecture fees and 
honoraria from Medscape. AMS reports XXXX. SJS reports receiving grant support, fees for 
serving as a principal investigator of a clinical trial, and consulting fees from Actelion and 
AstraZeneca, grant support and fees for serving as a principal investigator of a clinical trial 
from Corvia Medical, consulting fees from Amgen, Cardiora, Eisai, Merck, Sanofi, Pfizer, 
MyoKardia, Axon Therapies, Ionis Pharmaceuticals, and Bristol- Myers Squibb, fees for 
serving as a principal investigator of a clinical trial and consulting fees from Bayer, fees for 
serving on a steering committee and consulting fees from Boehringer Ingelheim and 
Ironwood Pharma–Cyclerion Therapeutics, fees for serving on a steering committee from 
United Therapeutics, and fees for serving on a clinical-events committee from CVRx. DJvV 
reports receiving fees for serving on a steering committee and travel support from ARCA 
Biopharma and Corvia Medical. FZ reports receiving fees for serving on a steering 
committee from Janssen, Bayer, Boston Scientific, CVRx, and Boehringer Ingelheim, 
consulting fees from Amgen, Vifor Pharma–Fresenius, Cardior, Cereno Pharmaceutical, Ap- 
plied Therapeutics, and Merck, and consulting fees and fees for serving on a steering 
committee from AstraZeneca and serving as founder of cardiorenal and CVCT. MRZ reports 
grants and personal fees from Novartis for being a member of the PARAGON-HF Executive 
23 
 
Steering Committee and a local investigator; personal fees from Abbott for serving on the 
executive committee of the GUIDE-HF trial, personal fees for consulting on product 
development from Boston Scientific, grants and personal fees for serving on the Executive 
Steering Committee and being a local investigator for the BeAT HF trial from CVRx; 
personal fees for serving on the Eligibility Committee of the SOLVE trial from EBR, 
personal fees for serving on the Clinical Events Committee of the SIRONA trial from 
Endotronics, personal fees for serving on the Executive Steering Committee of the 
CAPACITY HFpEF trial from Ironwood, personal fees for serving on the Data Safety 
Monitoring Board, Ertugliflozin (MK-8835/PF-04971729) trial from Merck; grants and 
personal fees for serving on the Executive Steering Committee, Revamp Trial, Alleviate 
Trial, Link HF trial, Intervene trial and being a local investigator from Medtronic; personal 
fees for consulting for product development from Myokardia, and personal fees for serving 
on the Eligibility Committee of the RELIEVE trial from V Wave. MC reports XXX. EG 
reports receiving grant support, consulting fees, lecture fees, and travel support from 
Novartis, consulting fees, lecture fees, and travel support from Servier and Boehringer 
Ingelheim, consulting fees and lecture fees from Medtronic, consulting fees and travel 
support from Janssen Pharmaceuticals, and consulting fees from Bayer. TK reports receiving 
lecture fees, fees for serving on an advisory board, and travel support from Novartis and 
lecture fees, consulting fees, and fees for serving on an advisory board from AstraZeneca. 
AK reports XXX. ML reports receiving honoraria and lecture fees from Servier, 
AstraZeneca, Gedeon Richter, Boehringer Ingelheim, and Bausch Health. NKS reports 
research grants from Novartis and Merck. BC reports receiving consulting fees from 
AOBiome, Biogen, Boehringer Ingelheim, Corvia Medical, Gilead Sciences, and MyoKardia. 
PSJ reports receiving grant support from Boehringer Ingelheim and fees for serving on an 
advisory board from Cytokinetics. SDS reports grants paid to his institution for chairing 
PARAGON-HF from Novartis; grants paid to Brigham and Women’s Hospital from 
Alnylam, Amgen, AstraZeneca, Bayer, Bellerophon, BMS, Celladon, Cytokinetics, Gilead, 
24 
 
Celladon, Eidos, GSK, Ionis, Lone Star Heart, Mesoblast, MyoKardia, NIH/NHLBI, 
Novartis, Sanofi Pasteur, and Theracos; and consulting fees from Alnylam, Amgen, 
AoBiome, AstraZeneca, Bayer, BMS, Cardiac Dimensions, Corvia, Cytokinetics, Daichi-
Sankyo; Gilead, GSK, Ironwood, Janssen, Merck, MyoKardia, Novartis, Quantum Genomics, 
Roche, Takeda, Tenaya, and Theracos.  
 
 
 
 
 
. 
 
  
25 
 
REFERENCES 
1. Dewan P, Rørth R, Jhund PS, Shen L, Raparelli V, Petrie MC, Abraham WT, Desai  AS, 
Dickstein K, Køber L, Mogensen UM, Packer M, Rouleau JL, Solomon SD, Swedberg K, 
Zile MR, McMurray JJV. Differential Impact of Heart Failure With Reduced Ejection 
Fraction on Men and Women. J Am Coll Cardiol. 2019;73:29-40. 
 
2. Gori M, Lam CS, Gupta DK, Santos AB, Cheng S, Shah AM, Claggett B, Zile MR 
Kraigher-Krainer E, Pieske B, Voors AA, Packer M, Bransford T, Lefkowitz M, 
McMurray JJ, Solomon SD; PARAMOUNT Investigators. Sex-specific 
cardiovascular structure and function in heart failure with preserved ejection fraction. 
Eur J Heart Fail. 2014;16:535-542. 
 
3. Stolfo D, Uijl A, Vedin O, Strömberg A, Faxén UL, Rosano GMC, Sinagra G, 
Dahlström U, Savarese G. Sex-Based Differences in Heart Failure Across the Ejection 
Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications. JACC 
Heart Fail. 2019;7:505-515.  
 
4. Beale AL, Nanayakkara S, Segan L, Mariani JA, Maeder MT, van Empel V, Vizi D, 
Evans S, Lam CSP, Kaye DM. Sex Differences in Heart Failure With Preserved 
Ejection Fraction Pathophysiology: A Detailed Invasive Hemodynamic and 
Echocardiographic Analysis. JACC Heart Fail. 2019;7:239-249.  
 
5. Beale AL, Meyer P, Marwick TH, Lam CSP, Kaye DM. Sex Differences in 
Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure 
With Preserved Ejection Fraction. Circulation. 2018;138:198-205.  
 
26 
 
6. Tibrewala A, Yancy CW. Heart Failure with Preserved Ejection Fraction in Women. 
Heart Fail Clin. 2019;15:9-18.  
 
7. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, 
González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, 
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, 
Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: 
The Task Force for the diagnosis and treatment of acute and chronic heart failure of 
the European Society of Cardiology (ESC)Developed with the special contribution of 
the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200.  
 
8. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, 
Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi 
FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA 
Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart 
Failure: A Report of the American College of Cardiology/American Heart 
Association Task Force on Clinical Practice Guidelines and the Heart Failure Society 
of America. Circulation. 2017;136:e137-e161.  
 
9. Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni 
AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van 
Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray 
JJV. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With 
Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. 
JACC Heart Fail. 2017;5:471-482.  
 
27 
 
10. Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker SD, 
Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, 
Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, Filippatos G, 
Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, 
Lelonek M, Linssen G, Lund LH, O'Meara E, Merkely B, Milicic D, Oh BH, Perrone 
SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS Jr, 
Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J Jr, Yilmaz MB, 
Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, 
Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile 
MR, McMurray JJV. Baseline Characteristics of Patients With Heart Failure and 
Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail. 
2018;11:e004962.  
 
11. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, 
Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, 
Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, 
Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, 
Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; 
PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in 
Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381:1609-1620.  
 
12. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of  the 
Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart 
failure. J Am Coll Cardiol. 2000;35:1245-1255.  
 
28 
 
13. Claggett B, Pocock S, Wei LJ, Pfeffer MA, McMurray JJV, Solomon SD. 
Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized 
Clinical Trials. Circulation. 2018;138:570-577.  
 
14. Wittes J. On looking at subgroups. Circulation. 2009;119:912-915. 
 
15. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment 
effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93-98.  
 
16. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--
reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189-2194.  
 
17. Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, Bala MM, Bassler D, Mertz  
D, Diaz-Granados N, Vandvik PO, Malaga G, Srinathan SK, Dahm P, Johnston BC, 
Alonso-Coello P, Hassouneh B, Walter SD, Heels-Ansdell D, Bhatnagar N, Altman 
DG, Guyatt GH. Credibility of claims of subgroup effects in randomised controlled 
trials: Systematic review. BMJ. 2012;344 e1553.  
 
18. Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration. 
Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, 
LV Mass, and Systolic Function: The EchoNoRMAL Study. JACC Cardiovasc 
Imaging. 2015;8:656-665.  
 
19. Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile MR, 
Voors AA, Lefkowitz MP, Packer M, McMurray JJ, Solomon SD; PARAMOUNT 
Investigators. Impaired systolic function by strain imaging in heart failure with 
preserved ejection fraction. J Am Coll Cardiol. 2014:63:447-456. 
29 
 
 
20.      Föll D, Jung B, Schilli E, Staehle F, Geibel A, Hennig J, Bode C, Markl M. Magnetic 
resonance tissue phase mapping of myocardial motion: new insight in age and gender. 
Circ Cardiovasc Imaging. 2010;3:54-64. 
 
21. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-
related ventricular-vascular stiffening: a community-based study. Circulation. 
2005;112:2254-2262.  
 
22. Chirinos JA. Arterial stiffness: basic concepts and measurement techniques. J 
Cardiovasc Transl Res. 2012;5:243-255.  
 
23. Lam CS, Cheng S, Choong K, Larson MG, Murabito JM, Newton-Cheh C, Bhasin S, 
McCabe EL, Miller KK, Redfield MM, Vasan RS, Coviello AD, Wang TJ. Influence 
of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol. 
2011;58:618-626.  
 
24.   Clerico A, Passino C, Emdin M. When gonads talk to the heart sex hormones and 
cardiac endocrine function. J Am Coll Cardiol. 2011;58:627-628. 
 
25.  Glisic M, Rojas LZ, Asllanaj E, Vargas KG, Kavousi M, Ikram MA, Fauser BCJM, 
Laven JSE, Muka T, Franco OH. Sex steroids, sex hormone-binding globulin and 
levels of N-terminal pro-brain natriuretic peptide in postmenopausal women. Int J 
Cardiol. 2018;261:189-195. 
 
26.  Ying W, Zhao D, Ouyang P, Subramanya V, Vaidya D, Ndumele CE, Sharma K, 
Shah SJ, Heckbert SR, Lima JA, deFilippi CR, Budoff MJ, Post WS, Michos ED. Sex 
30 
 
Hormones and Change in N-Terminal Pro-B-Type Natriuretic Peptide Levels: The 
Multi-Ethnic Study of Atherosclerosis. J Clin Endocrinol Metab. 2018;103:4304-
4314. 
 
27.  Moreau KL, Hildreth KL. Vascular Aging across the Menopause Transition in 
Healthy Women. Adv Vasc Med. 2014;pii: 204390. 
 
28.  Novella S, Pérez-Cremades D, Mompeón A, Hermenegildo C. Mechanisms 
underlying the influence of oestrogen on cardiovascular physiology in women. J 
Physiol. 2019;597:4873 4886.  
 
29.  Mannacio V, Di Tommaso L, Antignano A, De Amicis V, Stassano P, Pinna GB, 
Vosa C. Endothelial nitric oxide synthase expression in postmenopausal women: a 
sex-specific risk factor in coronary surgery. Ann Thorac Surg. 2012;94:1934-1939. 
 
30.  Cui R, Iso H, Pi J, Kumagai Y, Yamagishi K, Tanigawa T, Shimamoto T. 
Relationship between urinary cGMP excretion and serum total cholesterol levels in a 
general population. Atherosclerosis. 2005;179:379-386.  
 
31:  Salhotra S, Arora S, Anubhuti, Trivedi SS, Bhattacharjee J. Influence of menopause 
on biochemical markers of endothelial dysfunction-A case-control pilot study in 
North Indian population. Maturitas. 2009;62:166-170. 
 
32. Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE Inhibitor-Induced 
Angioedema: a Review. Curr Hypertens Rep. 2018;20:55.doi: 10.1007/s11906-018-
0859-x. 
 
31 
 
33. Reddy YNV, Iyer SR, Scott CG, Rodeheffer RJ, Bailey K, Jenkins G, Batzler A, 
Redfield MM, Burnett JC Jr, Pereira NL. Soluble Neprilysin in the General 
Population: Clinical Determinants and Its Relationship to Cardiovascular Disease. J 
Am Heart Assoc. 2019;8:e012943.  
 
34. Platz E, Jhund PS, Claggett BL, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, 
Solomon SD, McMurray JJ. Prevalence and prognostic importance of precipitating 
factors leading to heart failure hospitalization: recurrent hospitalizations and 
mortality. Eur J Heart Fail. 2018;20:295-303.  
 
35. Fajardo J, Cummings A, Brown E, Cuomo K, Rhodes P, Woodbury S, Gilotra N, 
Russell S, Judge D. Clinical pathway to screen for cardiac amyloidosis in heart failure 
with preserved ejection fraction. Amyloid. 2019;26:166-167.  
 
36. Linde C, Cleland JGF, Gold MR, Claude Daubert J, Tang ASL, Young JB, Sherfesee 
L, Abraham WT. The interaction of sex, height, and QRS duration on the effects of 
cardiac resynchronization therapy on morbidity and mortality: an individual-patient 
data meta-analysis. Eur J Heart Fail. 2018;20:780-791. 
 
37. Adams KF Jr, Patterson JH, Gattis WA, O'Connor CM, Lee CR, Schwartz TA, 
Gheorghiade M. Relationship of serum digoxin concentration to mortality and 
morbidity in women in the digitalis investigation group trial: a retrospective analysis. 
J Am Coll Cardiol. 2005;46:497-504.  
 
38. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O'Meara E, 
Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA; TOPCAT Investigators.  
32 
 
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients 
with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455-462.  
 
39.  Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger 
CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, 
Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K; Candesartan in Heart failure 
Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and 
Committees. Mortality and morbidity reduction with Candesartan in patients with 
chronic heart failure and left ventricular systolic dysfunction: results of the CHARM 
low-left ventricular ejection fraction trials. Circulation. 2004;110:2618-2626. 
 
40. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, 
Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and 
Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure.  N 
Engl J Med. 2014;371:993-1004.  
 
41.  Hsich EM, Piña IL. Heart failure in women: a need for prospective data. J Am Coll 
Cardiol. 2009;54:491-498. 
 
42. Rossello X, Ariti C, Pocock SJ, Ferreira JP, Girerd N, McMurray JJV, Van 
Veldhuisen DJ, Pitt B, Zannad F. Impact of mineralocorticoid receptor antagonists on 
the risk of sudden cardiac death in patients with heart failure and left-ventricular 
systolic dysfunction: an individual patient-level meta-analysis of three randomized-
controlled trials. Clin Res Cardiol. 2019;108:477-486. 
 
43. Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, 
Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM,  
33 
 
Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, 
Meyer S, Lam CSP; ASIAN-HF investigators, Voors AA. Identifying optimal doses 
of heart failure medications in men compared with women: a prospective, 
observational, cohort study. Lancet. 2019;394:1254-1263. 
 
44. Gan L, Langenickel T, Petruck J, Kode K, Rajman I, Chandra P, Zhou W, Rebello S, 
Sunkara G. Effects of age and sex on the pharmacokinetics of LCZ696, an 
angiotensin receptor neprilysin inhibitor. J Clin Pharmacol 2016; 56: 78-86.  
 
 
  
34 
 
Table 1. Baseline characteristics for women and men in PARAGON-HF.  
 
 Women 
(n=2479) 
Men 
(n=2317) 
P value 
Age – years 73.6±8.0 71.8±8.7 <0.001 
Age category    <0.001 
   50-59 143 (5.8) 232 (10.0)  
   60-69 562 (22.7) 676 (29.2)  
   70-79 1168 (47.1) 942 (40.7)  
   ≥80 606 (24.4) 467 (20.2)  
Region   0.003 
   Asia-Pacific and other 379 (15.3) 383 (16.5)  
   Central Europe 885 (35.7) 830 (35.8)  
   Latin America 222 (9.0) 148 (6.4)  
   North America 264 (10.6) 295 (12.7)  
   Western Europe 729 (29.4) 661 (28.5)  
Race   <0.001 
   Asian 287 (11.6) 320 (13.8)  
   Black 61 (2.5) 41 (1.8)  
   Other 124 (5.0) 56 (2.4)  
   White 2007 (81.0) 1900 (82.0)  
Duration of heart failure   0.41 
   0-3 months 417 (16.9) 356 (15.4)  
   3-6 months  319 (12.9) 267 (11.5)  
   6-12 months 309 (12.5) 307 (13.3)  
   1-2 years 340 (13.8) 339 (14.7)  
   2-5 years 508 (20.6) 485 (21.0)  
   >5 years 578 (23.4) 559 (24.2)  
Systolic blood pressure – mmHg 131±16 130±15 0.04 
Diastolic blood pressure – mmHg 74±11 74±10 0.99 
Pulse pressure – mmHg 57±15 56±14 0.029 
Heart rate – beats/min 71±12 70±12 0.047 
Left ventricular ejection fraction – % 58.9±7.9 56.0±7.6 <0.001 
Body mass index – kg/m2 30.4±5.2 30.0±4.8 0.001 
Body mass index >30 kg/m2 1272 (51.3) 1082 (46.7) 0.001 
Waist circumference – cm  101.8±14.5 107.6±14.7 <0.001 
   Abnormal* 1953 (82.8) 1339 (61.6) <0.001 
Waist/hip ratio  0.93±0.12 1.00±0.11 <0.001 
Estimated GFR – mL/min/1.73m2 60±18 65±20 <0.001 
Estimated GFR <60 mL/min/1.73m2 1320 (53.2) 1021 (44.1) <0.001 
N-terminal-pro B-type natriuretic peptide – pg/ml 836 (446-1601) 954 (496-1631) 0.002 
   In patients with atrial fibrillation† 1712 (1252-2360) 1508 (1124-2210) <0.001 
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   In patients without atrial fibrillation† 575 (378-1018) 625 (381-1103) 0.022 
Urinary cGMP/creatinine 129±70 120±61 0.013 
NYHA functional class   <0.001 
   I 49 (2.0) 88 (3.8)  
   II 1865 (75.3) 1841 (79.5)  
   III 554 (22.4) 378 (16.3)  
   IV 10 (0.4) 9 (0.4)  
KCCQ    
   Clinical summary score 70.8 (56.3-83.9) 79.2 (64.6-90.6) <0.001 
   Overall summary score 70.8 (55.7-83.6) 77.6 (63.5-88.8) <0.001 
Medical history    
   Atrial fibrillation† 725 (29.4) 827 (35.8) <0.001 
   Any history of atrial fibrillation 1280 (51.6) 1241 (53.6) 0.18 
   Angina pectoris 664 (26.8) 724 (31.2) <0.001 
   Myocardial infarction 389 (15.7) 694 (30.0) <0.001 
   Hypertension 2392 (96.5) 2192 (94.6) 0.002 
   Diabetes 1001 (40.4) 1061 (45.8) <0.001 
   Prior heart failure hospitalization 1113 (44.9) 1193 (51.5) <0.001 
   Stroke 256 (10.3) 252 (10.9) 0.53 
   Chronic obstructive pulmonary disease 286 (11.5) 384 (16.6) <0.001 
   Cancer 228 (9.2) 205 (8.9) 0.67 
   Anemia 366 (14.8) 341 (14.7) 0.96 
   Renal disease 589 (23.9) 635 (27.5) 0.004 
   Other vascular disease 266 (10.8) 354 (15.4) <0.001 
   Coronary artery bypass grafting 172 (6.9) 398 (17.2) <0.001 
   Percutaneous coronary intervention 369 (14.9) 608 (26.2) <0.001 
   Smoker (current or former) 546 (22.2) 1308 (56.8) <0.001 
   ACE inhibitor intolerance 155 (6.3) 107 (4.6) 0.013 
Treatments    
   Diuretic 2352 (94.9) 2233 (96.4) 0.011 
   Mineralocorticoid receptor antagonist 590 (23.8) 649 (28.0) <0.001 
   ACE inhibitor or ARB at screening 2145 (86.5) 1994 (86.1) 0.64 
   Beta-blocker 1985 (80.1) 1836 (79.2) 0.47 
   Calcium channel blocker 861 (34.7) 779 (33.6) 0.42 
   Digoxin 248 (10.0) 202 (8.7) 0.13 
   Nitrate 308 (12.4) 391 (16.9) <0.001 
   Statin 1503 (60.6) 1552 (67.0) <0.001 
   Antiplatelet 256 (10.3) 379 (16.4) <0.001 
   Anticoagulant 762 (30.7) 789 (34.1) 0.014 
Signs and symptoms    
   Dyspnea on effort 2316 (93.5) 2108 (91.1) 0.002 
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   Paroxysmal nocturnal dyspnea 108 (4.4) 83 (3.6) 0.17 
   Orthopnea 511 (20.6) 375 (16.2) <0.001 
   Edema 930 (37.6) 896 (38.7) 0.41 
   Rales 163 (6.6) 182 (7.9) 0.086 
   Third heart sound 57 (2.3) 54 (2.3) 0.94 
   Jugular venous distension 321 (13.0) 334 (14.6) 0.13 
   Fatigue 1328 (53.6) 1109 (48.0) <0.001 
 
* Defined as >88 cm in women and >102 cm in men 
† Defined as the presence of atrial fibrillation or atrial flutter on screening ECG 
Data are presented as mean ± standard deviation or median (interquartile range) for continuous measures and number 
(%) for categorical measures 
All drugs are at randomization unless otherwise specified 
GFR = glomerular filtration rate; cGMP = cyclic guanosine monophosphate; NYHA = New York Heart Association; 
KCCQ = Kansas City Cardiomyopathy Questionnaire; ACE = angiotensin-converting enzyme; ARB = angiotensin 
receptor blocker 
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Table 2. Outcomes for women and men in PARAGON-HF. 
 
 Women (n=2479) Men (n=2317)  
 All Sacubitril-valsartan 
(n=1241) 
Valsartan 
(n=1238) 
All Sacubitril-valsartan 
(n=1666) 
Valsartan 
(n=1151) 
Interaction P value 
Primary composite outcome        
   Number of events 923 391 532 980 503 477  
   Event rate (95% CI) 12.7 (11.9-13.6) 10.8 (9.8-11.9) 14.7 (13.5-16.0) 14.8 (13.9-15.8) 15.1 (13.8-16.5) 14.6 (13.3-16.0)  
   Unadjusted rate ratio (95% CI)*  0.73 (0.59-0.90)  1.03 (0.84-1.25) 0.0168* 
   Adjusted rate ratio (95% CI)†  0.73 (0.60-0.90)  1.02 (0.83-1.24) 0.0225† 
Primary composite outcome plus 
urgent HF visits 
       
   Number of events 964 411 553 1034 523 511  
   Event rate (95% CI) 13.3 (12.5-14.2) 11.3 (10.3-12.5) 15.3 (14.1-16.6) 15.7 (14.7-16.6) 15.7 (14.4-17.1) 15.6 (14.3-17.0)  
   Unadjusted rate ratio (95% CI)*  0.73 (0.60-0.91)  1.00 (0.82-1.21) 0.0329* 
   Adjusted rate ratio (95% CI)†  0.74 (0.61-0.91)  0.99 (0.81-1.20) 0.0449† 
Total hospitalizations for HF        
   Number of events 738 298 440 749 392 357  
   Event rate (95% CI) 10.2 (9.5-11.0) 8.2 (7.3-9.2) 12.2 (11.1-13.3) 11.3 (10.6-12.2) 11.8 (10.6-13.0) 10.9 (9.8-12.1)  
   Unadjusted rate ratio (95% CI)*  0.67 (0.53-0.85)     1.07 (0.85-1.34) 0.0046* 
   Adjusted rate ratio (95% CI)†  0.67 (0.54-0.84)  1.06 (0.84-1.34) 0.0048† 
CV death        
   Number of events 185 93 92 231 111 120  
   Event rate (95% CI) 2.6 (2.2-2.9) 2.6 (2.1-3.1) 2.5 (2.1-3.1) 3.5 (3.1-4.0) 3.3 (2.8-4.0) 3.7 (3.1-4.4)  
   Unadjusted hazard ratio (95% CI)*  1.02 (0.76-1.36)  0.90 (0.70-1.17) 0.5763* 
   Adjusted hazard ratio (95% CI)†  1.05 (0.78-1.41)  0.88 (0.67-1.14) 0.3688† 
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Death from any cause        
   Number of events 312 153 159 379 189 190  
   Event rate (95% CI) 4.3 (3.9-4.8) 4.2 (3.6-4.9) 4.4 (3.8-5.1) 5.7 (5.2-6.3) 5.7 (4.9-6.5) 5.8 (5.0-6.7)  
   Unadjusted hazard ratio (95% CI)*  0.96 (0.77-1.20)  0.97 (0.80-1.19) 0.9040* 
   Adjusted hazard ratio (95% CI)†  0.99 (0.79-1.24)  0.95 (0.77-1.17) 0.8703† 
First hospitalization for HF or CV 
death 
       
   Number of events 524 239 285 559 287 272  
   Event rate (95% CI) 7.9 (7.3-8.6) 7.1 (6.3-8.1) 8.8 (7.8-9.8) 9.3 (8.5-10.1) 9.5 (8.4-10.6) 9.1 (8.0-10.2)  
   Unadjusted hazard ratio (95% CI)*  0.81 (0.68-0.96)  1.03 (0.87-1.21) 0.0440* 
   Adjusted hazard ratio (95% CI)†  0.78 (0.65-0.92)  1.03 (0.87-1.22) 0.0213† 
First hospitalization for HF        
   Number of events 417 183 234 421 222 199  
   Event rate (95% CI) 6.3 (5.7-7.0) 5.5 (4.7-6.3) 7.2 (6.3-8.2) 7.0 (6.3-7.7) 7.3 (6.4-8.4) 6.6 (5.8-7.6)  
   Unadjusted hazard ratio (95% CI)*  0.75 (0.62-0.91)  1.08 (0.89-1.31) 0.0070* 
   Adjusted hazard ratio (95% CI)†  0.72 (0.59-0.87)  1.09 (0.90-1.33) 0.0025† 
Change in NYHA from baseline to 8 
months 
       
   Improved – no. (%) 344 (14.5) 193 (16.4) 151 (12.7) 292 (13.0) 154 (13.5) 138 (12.4)  
   Unchanged – no. (%) 1817 (76.8) 881 (74.9) 936 (78.6) 1742 (77.4) 886 (77.7) 856 (77.1)  
   Worsened – no. (%) 206 (8.7) 102 (8.7) 104 (8.7) 217 (9.6) 100 (8.8) 117 (10.5)  
   Unadjusted odds ratio (95% CI)*‡   1.43 (1.02-2.03)  1.45 (1.01-2.07) 0.9791* 
   Adjusted odds ratio (95% CI)†‡  1.45 (1.03-2.06)  1.46 (1.02-2.09) 0.9890† 
Change in KCCQ clinical summary 
score from baseline to 8 months 
       
   Change -1.3±0.4 -1.6±0.5 -1.0±0.5 -2.9±0.4 -1.5±0.5 -4.3±0.5  
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   Difference  -0.6 (-2.1 to 0.8)  2.8 (1.3 to 4.3) 0.0013* 
0.0032 
   Increase ≥5 points – no. (%) 761 (33.3) 386 (34.0) 375 (32.7) 640 (29.2) 357 (32.0) 283 (26.3)  
   Unadjusted odds ratio (95% CI)*§  1.09 (0.81-1.46)  1.57 (1.14-2.15) 0.1080* 
   Adjusted odds ratio (95% CI)†§  1.11 (0.83-1.50)  1.55 (1.13-2.13)  0.1602† 
Renal composite outcome        
   Number of events 48 16 32 49 17 32  
   Event rate (95% CI) 0.7 (0.5-0.9) 0.4 (0.3-0.7) 0.9 (0.6-1.3) 0.7 (0.6-1.0) 0.5 (0.3-0.8) 1.0 (0.7-1.4)  
   Unadjusted hazard ratio (95% CI)*  0.49 (0.27-0.89)  0.53 (0.29-0.95) 0.8956* 
   Adjusted hazard ratio (95% CI)†  0.46 (0.25-0.84)  0.47 (0.26-0.86) 0.9714† 
New-onset atrial fibrillation      
   Number of events 144 84  60 118  53 65  
   Event rate (95% CI) 2.1 (1.7-2.4) 2.4 (1.9-3.0) 1.7 (1.3-2.2) 1.8 (1.5-2.2) 1.6 (1.2-2.1) 2.1 (1.6-2.6)  
   Unadjusted hazard ratio (95% CI)*  1.41 (1.02-1.97)  0.79 (0.55-1.13) 0.0189* 
   Adjusted hazard ratio (95% CI)†  1.43 (1.02-1.99)  0.78 (0.54-1.12) 0.0139† 
Change in NT-proBNP from baseline 
to 1 year 
     
   Change – pg/ml -114±39 -182±55 -45±55 -133±53 -259±73 2±76  
   Difference  -137 (-289 to 15)  -261 (-468 to -54) 0.3573* 
0.3764† 
Change in urinary cGMP/creatinine 
from baseline to 1 year 
     
   Change  -22.4±2.5 4.7±3.6 -49.9±3.6 -20.5±2.2 5.8±3.0 -48.7±3.2  
   Difference  54.6 (44.6 to 64.5)  54.5 (45.8 to 63.1) 0.9935* 
0.9087† 
40 
 
Change in systolic blood pressure from 
baseline to 8 months 
     
   Change – mmHg  1.9±0.3 -0.3±0.5 4.1±0.5 0.8±0.3 -1.4±0.5 3.1±0.5  
   Difference  -4.3 (-5.6 to -3.0)  -4.6 (-5.9 to -3.3) 0.8058* 
0.8727† 
Change in pulse pressure from 
baseline to 8 months 
     
   Change – mmHg  1.2±0.3 -0.3±0.4 2.6±0.4 0.6±0.3 -0.9±0.4 2.2±0.4  
   Difference  -2.9 (-4.0 to -1.8)  -3.1 (-4.2 to -2.0) 0.8109* 
0.9559† 
 
Event rate is number of events per 100 person-years. 
Plus-minus values are means ± standard error. 
* Model stratified by or adjusted for region 
† Model adjusted for age, heart rate, systolic blood pressure, body mass index, N-terminal pro-B-type natriuretic peptide level (log), estimated glomerular filtration rate, New York 
Heart Association functional class, left ventricular ejection fraction, prior heart failure hospitalization, myocardial infarction, diabetes, smoking, atrial fibrillation (except for time to 
new-onset atrial fibrillation) and either stratified by or adjusted for region 
Unadjusted models for change in New York Heart Association functional class, Kansas City Cardiomyopathy Questionnaire clinical summary score, N-terminal pro-B-type natriuretic 
peptide level, urinary cGMP/creatinine, systolic blood pressure and pulse pressure also include the baseline value. 
‡ Odds ratio for improvement 
§ Odds ratio for increase ≥5 points 
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Table 3. Tolerability and adverse events in women and men in PARAGON-HF 
 Women (n=2479) Men (n=2317) Interaction  
P value 
 All 
 
Sacubitril-valsartan  
(n=1241) 
Valsartan 
(n=1238) 
All 
 
Sacubitril-valsartan  
(n=1666) 
Valsartan 
(n=1151) 
 
Hypotension  317 (12.8) 195 (15.7) 122 (9.9) 320 (13.8) 185 (15.9) 135 (11.7) 0.3796* 
0.5045† 
Elevated serum creatinine  
 
       
   ≥2.0 mg/dl 181 (7.3) 75 (6.0) 106 (8.6) 408 (17.6) 186 (16.0) 222 (19.3) 0.4070* 
0.3638† 
   ≥2.5 mg/dl 58 (2.3) 28 (2.3) 30 (2.4) 148 (6.4) 69 (5.9) 79 (6.9) 0.8181* 
0.8860† 
   ≥3.0 mg/dl 22 (0.9) 12 (1.0) 10 (0.8) 56 (2.4) 26 (2.2) 30 (2.6) 0.5118* 
0.6355† 
Elevated serum potassium  
 
       
   >5.5 mmol/l 330 (13.3) 160 (12.9) 170 (13.7) 347 (15.0) 156 (13.4) 191 (16.6) 0.2515* 
0.1085† 
   >6.0 mmol/l 86 (3.5) 35 (2.8) 51 (4.1) 90 (3.9) 40 (3.4) 50 (4.3) 0.6491* 
0.7087† 
Angioedema  14 (0.6) 11 (0.9) 3 (0.2) 4 (0.2) 3 (0.3) 1 (0.1) 0.8840* 
0.6968† 
Liver-related adverse event  
 
143 (5.8) 64 (5.2) 79 (6.4) 186 (8.0) 87 (7.5) 99 (8.6) 0.7200* 
0.7360† 
Target dose  
 
1368 (82.6) 675 (80.6) 693 (84.5) 1314 (84.5) 665 (83.3) 649 (85.7) - 
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Discontinuation for reasons other than 
death  
679 (27.4) 336 (27.1) 343 (27.7) 569 (24.6) 274 (23.5) 295 (25.6) - 
 
Data are presented as number (%). 
Hypotension is defined as systolic blood pressure below 100 mmHg. 
* Model stratified by or adjusted for region 
† Model adjusted for age, heart rate, systolic blood pressure, body mass index, N-terminal pro-B-type natriuretic peptide level (log), estimated glomerular filtration rate, New York 
Heart Association functional class, left ventricular ejection fraction, prior heart failure hospitalization, myocardial infarction, diabetes, smoking, atrial fibrillation and region 
For creatinine, the multivariable model included baseline creatinine rather than estimated glomerular filtration rate. 
For potassium, the multivariable model also included baseline potassium. 
 
 
 
 
 
 
 
 
 
 
43 
 
Figure 1. Cumulative hazard estimate for the primary composite outcome and total 
hospitalizations for heart failure (first and repeat) according to sex and treatment in 
PARAGON-HF.  
A. Cumulative hazard estimate for the primary composite outcome. B. Cumulative hazard 
estimate for total hospitalizations (first and repeat).  
 
Figure 2. Treatment effect in women and men in PARAGON-HF according to left 
ventricular ejection fraction.  
A. Treatment effect on the primary composite outcome in women. B. Treatment effect on the 
primary composite outcome in men. C. Treatment effect on total hospitalizations for heart 
failure in women. D. Treatment effect on total hospitalizations for heart failure in men. Rate 
ratios and 95% confidence intervals shown. 
 
 


